Pharsight

1. Anjeso patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8512727	BAUDAX	Nanoparticulate meloxicam formulations	Dec, 2022 (1 year, 4 months ago)
US10463673	BAUDAX	Nanoparticulate meloxicam formulations	Feb, 2024 (2 months ago)
US10471067	BAUDAX	Nanoparticulate meloxicam formulations	Feb, 2024 (2 months ago)
US11253478	BAUDAX	Reduction of flake-like aggregation in nanoparticulate active agent compositions	May, 2030 (6 years from now)
US9974746	BAUDAX	Reduction of flake-like aggregation in nanoparticulate active agent compositions	May, 2030 (6 years from now)
US10709713	BAUDAX	Nanoparticulate meloxicam formulations	May, 2030 (6 years from now)
US10881663	BAUDAX	Method of treating pain in elderly patients with mild renal impairment	Mar, 2039 (14 years from now)
US11458145	BAUDAX	Methods of administering intravenous meloxicam in a bolus dose	Mar, 2039 (14 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Product(NP)	Feb 20, 2023

Market Authorisation Date: 20 February, 2020

Treatment: Management of moderate-to-severe pain by intravenous injection; Management of moderate-to-severe pain by injection; Management of moderate-to-severe pain by intravenous injection in patients with mild...

Dosage: SOLUTION;INTRAVENOUS

Strength	Dosage	Availability
30MG/ML (30MG/ML) Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	SOLUTION;INTRAVENOUS	Discontinued

ANJESO family patents

2. Meloxicam patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6184220	AVONDALE PHARMS	Oral suspension of pharmaceutical substance	Mar, 2019 (5 years ago)
US6184220 (Pediatric)	AVONDALE PHARMS	Oral suspension of pharmaceutical substance	Sep, 2019 (4 years ago)

Drug Exclusivity	Drug Exclusivity Expiration
Pediatric Exclusivity(PED)	Feb 11, 2013
Orphan Drug Exclusivity(ODE)	Aug 11, 2012

Market Authorisation Date: 01 June, 2004

Treatment: NA

Dosage: SUSPENSION;ORAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
7.5 mg/5 mL	17 Dec, 2009	1		25 Sep, 2019	Extinguished

Strength	Dosage	Availability
7.5MG/5ML Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	SUSPENSION;ORAL	Prescription

MELOXICAM family patents

3. Qmiiz Odt patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8545879	TERSERA	Fast disintegrating compositions of meloxicam	Aug, 2030 (6 years from now)

Market Authorisation Date: 19 October, 2018

Treatment: NA

Dosage: TABLET, ORALLY DISINTEGRATING;ORAL

Strength	Dosage	Availability
7.5MG	TABLET, ORALLY DISINTEGRATING;ORAL	Discontinued
15MG	TABLET, ORALLY DISINTEGRATING;ORAL	Discontinued

QMIIZ ODT family patents

4. Vivlodex patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9526734	ICEUTICA OPERATIONS	Formulation of meloxicam	Mar, 2033 (8 years from now)
US9808468	ICEUTICA OPERATIONS	Formulation of meloxicam	Mar, 2035 (10 years from now)
US9649318	ICEUTICA OPERATIONS	Formulation of meloxicam	Mar, 2035 (10 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Product(NP)	Oct 22, 2018

Market Authorisation Date: 22 October, 2015

Treatment: Management of osteoarthritis pain by administering 10 mg of meloxicam

Dosage: CAPSULE;ORAL